Levonorgestrel
- Generic Name
- Levonorgestrel
- Brand Names
- Afirmelle 28 Day, Aftera, Alesse, Altavera 28 Day, Amethia 91 Day, Amethyst, Ashlyna 91 Day, Aubra 28 Day, Aviane 28, Ayuna 28 Day Pack, Balcoltra 28 Day, Bionafem, Camrese 91 Day, Camreselo 91 Day, Chateal 28 Day, Climara Pro, Curae, Daysee 91 Day, Delyla 28 Day, Dolishale 28 Day, Econtra, Enpresse 28 Day, Fallback Solo, Falmina 28 Day, Fayosim 91 Day, Her Style, Iclevia 91 Day, Indayo, Introvale 91 Day, Jaimiess 91 Day, Jolessa 91 Day, Joyeaux 28 Day, Kurvelo, Kyleena, Larissia 28 Day Pack, Levonest 28 Day, Levora 0.15/30 28 Day, Liletta, Lillow 28 Day, Lo Simpesse, LoJaimiess, Loseasonique, Lutera 28 Day, Marlissa 28 Day, Min-ovral, Mirena, Morning After, My Choice, My Way, Myzilra 28 Day, New Day, Next Choice, Next Choice One Dose, Opcicon One-step, Option 2, Orsythia 28 Day, Plan B, Plan B One-step, Portia 28 Day, Preventeza, Quartette 91 Day Pack, React, Rivelsa 91 Day, Seasonale, Seasonique, Setlakin 91 Day, Simpesse, Skyla, Sronyx 28 Day, Take Action, Triquilar, Trivora 28 Day, Twirla 3 Count Weekly Patch, Tyblume 28 Day, Vienva 28 Day
- Drug Type
- Small Molecule
- Chemical Formula
- C21H28O2
- CAS Number
- 797-63-7
- Unique Ingredient Identifier
- 5W7SIA7YZW
- Background
Levonorgestrel (LNG) is a synthetic progestogen similar to Progesterone used in contraception and hormone therapy. Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of these devices are known as Jaydess, Kyleena, and Mirena....
- Indication
Emergency contraception
...
- Associated Conditions
- Endometrial Hyperplasia, Endometriosis, Heavy Menstrual Bleeding, Hypermenorrhea, Postmenopausal Osteoporosis, Pregnancy, Moderate Menopausal Vasomotor Symptoms, Severe Vasomotor Symptoms Associated With Menopause
- Associated Therapies
- Emergency Contraception
To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 174
- Registration Number
- NCT02490774
Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 100
- Registration Number
- NCT02480647
- Locations
- 🇧🇷
Nelsilene Mota Carvalho, Campinas, São Paulo, Brazil
Bay98-7196, Dose Finding / POC Study
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 319
- Registration Number
- NCT02203331
Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-06-09
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 20
- Registration Number
- NCT02159131
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
- First Posted Date
- 2014-02-20
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 123
- Registration Number
- NCT02067663
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-12
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 60
- Registration Number
- NCT01789879
- Locations
- 🇺🇬
Infectious Diseases Institute, Kampala, Uganda
Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Thomas Cherpes, DVM, MD
- Target Recruit Count
- 7
- Registration Number
- NCT01750476
- Locations
- 🇺🇸
UPMC Adolescent Clinic of Oakland, Pittsburgh, Pennsylvania, United States
Therapeutic Equivalence Trial of Two Hormonal-IUDs in Patients With Heavy Menstrual Bleeding
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- Uteron Pharma S.A.
- Target Recruit Count
- 280
- Registration Number
- NCT01695902
Improving the Treatment for Women With Early Stage Cancer of the Uterus
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2012-09-17
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Queensland Centre for Gynaecological Cancer
- Target Recruit Count
- 165
- Registration Number
- NCT01686126
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺King Edward Memorial Hospital for Women, Perth, Western Australia, Australia
🇦🇺Royal Women's Hospital, Carlton, Victoria, Australia
Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches
- First Posted Date
- 2012-06-20
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Agile Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT01623466
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath